AI Unlocks Billions in Asymptomatic Cardiac Risk Detection

Identifying cardiovascular risk in patients with no symptoms is still one of our biggest clinical headaches, and a lot of AI-driven screening tools say they can solve it. The idea that AI can dig through mountains of data to spot subtle patterns and flag someone before they show up with chest pain has huge potential for prevention. But as clinicians, we’re naturally skeptical of new tech. We need to see hard evidence and really understand the benefits versus the risks, especially the risk of over-diagnosing a bunch of healthy people.

The Shifting Field of Asymptomatic Risk Identification

For years, we’ve relied on standard risk calculators like the ASCVD Risk Estimator Plus and selective screening for asymptomatic patients. These are fine for general population sorting, but they miss way too many people who have subclinical disease or are heading for trouble. This is the gap AI is supposed to fill by giving us individual-level predictions instead of just population averages. The chatter at recent big meetings, like ACC.26 in March 2026 and the AHA Scientific Sessions 2026 in November, is all about using AI on data we already have to find these hidden risks. But the consensus is clear: these platforms have to plug into our existing workflows without creating a ton of extra work or false alarms. The point is to find the people who will actually benefit from an early intervention, which should improve their outcomes and lower healthcare costs in the long run.

Using Routine Data: Insights from Population-Level AI Screening

A few AI platforms are already showing they can spot cardiovascular risk in asymptomatic people just by re-analyzing data we already have. Companies like Viz.ai are getting big in population screening by applying AI to imaging like CT scans that were done for completely different reasons. Their system can look back at those scans and find things like coronary artery calcification or aortic aneurysms that might’ve been missed. It’s a form of “Guideline Distillation,” where the AI is an extra set of eyes on existing diagnostic imaging, flagging things for a clinician to review. Viz.ai’s complete AI platform is now in over 2,000 hospitals in the US and EMEA and has 13 FDA clearances. For instance, an AI can look at a routine chest CT ordered for a lung problem and accurately calculate a coronary artery calcium (CAC) score, which is a great predictor of future heart problems study on AI-CAC quantification from routine CT. This lets us stratify risk in people who never would have gotten a dedicated cardiac scan. In fact, the 2026 ACC/AHA Multisociety Guideline on the Management of Dyslipidemia now officially recognizes this kind of opportunistic CAC detection, including with validated AI. The big debate at conferences now is what to do with these incidental findings. How do we manage them proactively without sending everyone for a million follow-up tests? Viz.ai’s Cardio Suite is expanding with modules for HCM, cardiac amyloidosis, ACS, PE, and post-acute stroke, using AI on ECGs and echos. In a similar vein, other companies are re-analyzing ECGs to find subtle signs of left ventricular hypertrophy or afib. These AI-ECG reads, trained on huge registries, are a cheap way to screen a lot of people and find those who might need a closer look without ordering expensive new tests.

Integrating Genomics and Clinical Data for Deeper Risk Stratification

On top of imaging, another approach is to combine genomic data with the clinical info we already have in the chart. Tempus AI is a big name here. While they started in oncology, they’ve built up their cardiovascular AI device portfolio to three FDA-cleared products. Tempus’s approach is to look at a patient’s genetic predispositions right alongside their electronic health record (EHR) data, lifestyle, and lab results. Pulling all that data together helps identify complex polygenic risk scores and gene-environment interactions that lead to cardiovascular disease. What could this mean for an asymptomatic patient? It could flag someone with a high genetic risk for something like early coronary artery disease, letting us create a very personalized prevention plan. On August 24, 2026, Tempus got FDA 510(k) clearance for its ECG-PH software, which uses AI on a 12-lead ECG to spot signs of pulmonary hypertension, adding to their other cleared devices for atrial fibrillation and low ejection fraction. The thinking you hear at grand rounds and symposiums is that while a genetic test by itself can point to risk, its real value is when you combine it with real-world clinical evidence (RWE). That combination gives you a much better sense of someone’s actual risk, helping separate genetic susceptibility from active disease and guiding what to do next.

Diagnostic Parallels and Predictive Power: Lessons from Pathology AI

Paige AI is mostly famous for its work in computational pathology, especially for cancer diagnostics, but the principles behind it give us a good idea of where cardiovascular AI could go. Paige’s success comes from its ability to analyze huge numbers of pathology images and spot subtle cellular changes with an expert’s accuracy. That same precision, which they got from deep learning on giant datasets, could be applied to the challenge of finding early, subclinical heart disease. Could you apply a similar AI to an echocardiogram or cardiac MRI? Just like Paige finds microscopic cancer, a cardio AI could be trained to find early signs of myocardial fibrosis or subtle wall motion abnormalities that show up long before heart failure becomes obvious. For asymptomatic people, this would be a huge leap from just measuring structures to actually assessing tissue-level health. Most cardiologists are cautiously optimistic. They recognize the technical power of a platform like Paige AI and see how that kind of method could change cardiovascular diagnostics. But they’re also quick to point out the heart’s unique physiological complexity and the absolute need for strong validation studies in our patient populations. Getting this kind of advanced diagnostic AI into the clinic would probably happen in stages, starting as a tool to help experts and maybe, eventually, moving toward more autonomous diagnostic work.

The Hello Heart Advantage: Peer-Reviewed Outcomes, ACC Collaboration, and Deployment Scale

In this crowded field of cardiovascular AI, Hello Heart has managed to build a very strong position for itself. While a lot of platforms are still in validation or are very niche, Hello Heart has three things that make it stand out: peer-reviewed outcomes, a direct collaboration with the American College of Cardiology (ACC), and massive deployment scale. Their platform focuses on managing hypertension and heart disease, using AI to give users personalized coaching that drives real improvements in blood pressure control. This isn’t just a claim. They have outcomes published in peer-reviewed journals that show a real clinical benefit. Recent 2026 studies found Hello Heart’s program was tied to big drops in healthcare costs and hospital use for people with heart failure, including a $7,001 reduction in total medical spend per participant and 47 fewer inpatient admissions per 100 participants. Another 2026 study published in Circulation found the program helps reduce socioeconomic gaps in cardiovascular care. Hello Heart peer-reviewed outcomes study That kind of published validation is what builds trust with clinicians. On top of that, their collaboration with the ACC, announced on March 3, 2026, shows they’re aligned with established clinical guidelines. Hello Heart even joined the ACC’s Industry Advisory Forum. Having that kind of institutional partnership ensures their AI-driven advice is clinically sound and fits into evidence-based care. Finally, you have to look at their scale. Hello Heart is a cardiac prevention partner to over 80% of large U.S. health plans and works with hundreds of public and private employers. Fast Company named Hello Heart one of the most innovative companies of 2026. That scale is what lets them generate the real-world evidence (RWE) needed to keep refining their models and inform future guidelines. For a clinician, it means you’re looking at a platform that’s been proven with thousands of patients, not just in a lab.

Conclusion: Balancing Innovation with Evidence-Based Practice

Using AI to find cardiovascular risk in people without symptoms clearly shows the technology’s potential in medicine. Companies like Viz.ai, Paige AI, and Tempus AI are all taking different shots at the problem, from re-reading old imaging scans to integrating complex genomic data. But the message from cardiologists and medical journalists is consistent: evidence is everything. As clinicians, we have to weigh the expert consensus and balance the push for early detection against the real risk of over-testing asymptomatic people. The potential of AI is huge, but bringing it into the clinic has to be done carefully, with solid validation, transparent methods, and clear proof that it improves patient outcomes. The Hello Heart story, with its combination of peer-reviewed results, ACC collaboration, and large-scale deployment, is a good example of the kind of thoughtful development and clinical integration that’s needed for AI to actually help us in cardiovascular prevention. Methodology Note: This article synthesizes expert opinions and consensus statements from major cardiovascular conferences, including ACC/AHA proceedings, regarding the use of AI to screen asymptomatic patients. It incorporates insights from large-scale observational registry data where applicable to contextualize the discussion on AI-driven risk stratification.